1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma.
Saved in:
| Title: | 1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma. |
|---|---|
| Authors: | Schadendorf, D.1 (AUTHOR), Dummer, R.2 (AUTHOR), Ribas, A.3 (AUTHOR), Robert, C.4 (AUTHOR), Sullivan, R.J.5 (AUTHOR), King, A.6 (AUTHOR), Polli, A.7 (AUTHOR), di Pietro, A.8 (AUTHOR), Ascierto, P.A.9 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS700-S700. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 173099573 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Schadendorf%2C+D%2E%22">Schadendorf, D.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dummer%2C+R%2E%22">Dummer, R.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ribas%2C+A%2E%22">Ribas, A.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Robert%2C+C%2E%22">Robert, C.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sullivan%2C+R%2EJ%2E%22">Sullivan, R.J.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22King%2C+A%2E%22">King, A.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Polli%2C+A%2E%22">Polli, A.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22di+Pietro%2C+A%2E%22">di Pietro, A.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ascierto%2C+P%2EA%2E%22">Ascierto, P.A.</searchLink><relatesTo>9</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2023 Supplement 2, Vol. 34, pS700-S700. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=173099573 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2023.09.2996 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S700 Titles: – TitleFull: 1180TiP Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Schadendorf, D. – PersonEntity: Name: NameFull: Dummer, R. – PersonEntity: Name: NameFull: Ribas, A. – PersonEntity: Name: NameFull: Robert, C. – PersonEntity: Name: NameFull: Sullivan, R.J. – PersonEntity: Name: NameFull: King, A. – PersonEntity: Name: NameFull: Polli, A. – PersonEntity: Name: NameFull: di Pietro, A. – PersonEntity: Name: NameFull: Ascierto, P.A. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 10 Text: 2023 Supplement 2 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 34 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
